Haleon (NYSE:HLN – Get Free Report) is one of 27 publicly-traded companies in the “Toilet preparations” industry, but how does it compare to its competitors? We will compare Haleon to similar businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, dividends and risk.
This is a breakdown of current ratings and target prices for Haleon and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Toilet preparations” companies have a potential upside of 35.41%. Given Haleon’s competitors higher possible upside, analysts clearly believe Haleon has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Haleon and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Haleon||$13.43 billion||$1.31 billion||N/A|
|Haleon Competitors||$4.62 billion||$329.49 million||31.06|
Haleon has higher revenue and earnings than its competitors.
This table compares Haleon and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Haleon has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Haleon’s competitors have a beta of 33.93, suggesting that their average share price is 3,293% more volatile than the S&P 500.
Insider and Institutional Ownership
6.7% of Haleon shares are owned by institutional investors. Comparatively, 46.0% of shares of all “Toilet preparations” companies are owned by institutional investors. 19.2% of shares of all “Toilet preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Haleon Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.